| TTM
|
12/31/2025
|
12/31/2024
|
12/31/2023
|
12/31/2022
|
|
|---|---|---|---|---|---|
| Total Revenue
|
23,627 | 16,098 | 10,680 | 7,199 | 6,681 |
|
Cost of Revenue
|
-6,177 | -4,705 | -3,643 | -2,887 | -3,660 |
|
Gross Profit
|
17,450 | 11,393 | 7,037 | 4,312 | 3,021 |
| Selling, General and Administrative Expenses
|
-30,733 | -32,051 | -23,134 | -18,539 | -17,933 |
|
Research and Development Expenses
|
-20,994 | -20,596 | -16,965 | -14,424 | -14,690 |
|
Operating Income/Expenses
|
-51,727 | -52,647 | -40,099 | -32,963 | -32,623 |
|
Total Operating Profit/Loss
|
-34,277 | -41,254 | -33,062 | -28,651 | -29,602 |
| Total Net Finance Income/Expense
|
1,069 | 1,070 | 1,436 | 775 | 919 |
| Net Investment Income
|
820 | -2,134 | 3,808 | -575 | 2,825 |
| Irregular Income/Expenses
|
-- | -- | -- | 0 | -2,524 |
|
Non-Operating Income/Expenses, Total
|
1,889 | -1,064 | 5,244 | 200 | 1,220 |
|
Pretax Income
|
-32,388 | -42,318 | -27,818 | -28,451 | -28,382 |
| Provision for Income Tax
|
-102 | -252 | 2 | 128 | -287 |
|
Net Income from Continuing Operations
|
-32,490 | -42,570 | -27,816 | -28,323 | -28,669 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
-32,490 | -42,570 | -27,816 | -28,323 | -28,669 |
|
Net Income after Non-Controlling/Minority Interests
|
-32,490 | -42,570 | -27,816 | -28,323 | -28,669 |
|
Net Income Available to Common Stockholders
|
-32,490 | -42,570 | -27,816 | -28,323 | -28,669 |
|
Diluted Net Income Available to Common Stockholders
|
-32,490 | -42,570 | -27,816 | -28,323 | -28,669 |
| Basic EPS
|
-0.94 | -1.41 | -1.12 | -1.34 | -1.38 |
| Diluted EPS
|
-0.94 | -1.41 | -1.12 | -1.34 | -1.38 |
|
Basic Weighted Average Shares Outstanding
|
34,945.20 | 30,232.97 | 24,765.50 | 21,182.56 | 20,829.86 |
|
Diluted Weighted Average Shares Outstanding
|
34,945.20 | 30,232.97 | 24,765.50 | 21,182.56 | 20,829.86 |
|
Reported Normalized Basic EPS
|
0.60 | 0.60 | -- | -- | -- |
| Income Statement, Supplemental
|
|||||
|
EBIT
|
-33,457 | -43,388 | -29,254 | -29,226 | -29,011 |
|
EBITDA
|
-32,980 | -42,828 | -28,318 | -28,297 | -27,407 |
|
Normalized EBITDA
|
-29,420 | -37,338 | -25,737 | -24,880 | -20,370 |
|
Normalized Income
|
-29,854.89 | -38,506.30 | -25,235.19 | -24,921.37 | -22,803.12 |
|
Total Unusual Items
|
3,560 | 5,490 | 2,581 | 3,417 | 7,037 |
|
Total Unusual Items Excluding Goodwill
|
3,560 | 5,490 | 2,581 | 3,417 | 4,513 |
12/31/2022 - 7/10/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade